Abstract
Objective
To report a case of anti-glomerular basement membrane disease (anti-GBM disease) during
alemtuzumab treatment of a relapsing–remitting multiple sclerosis (RRMS) patient.
Design
Case report.
Setting
Outpatient neurology research protocol.
Patient
A 35-year-old white female receiving alemtuzumab for RRMS in a clinical research protocol
developed symptoms leading to diagnosis of anti-GBM disease.
Main outcome measure
Patient response to the treatment of anti-GBM disease and RRMS.
Results
Early identification and treatment of anti-GBM disease resolved clinical symptoms
and preserved renal function. Alemtuzumab treatment of RRMS resolved initial MS symptoms
and appears to have controlled active disease to date.
Conclusion
Close monitoring for potential side effects of alemtuzumab treatment in RRMS resulted
in a positive outcome when anti-GBM disease was recognized and treated early.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- An unusual case of pulmonary-renal syndrome associated with defects in type IV collagen composition and anti-glomerular basement membrane autoantibodies..American Journal of Kidney Diseases. 2005; 45: 743-748
- Anti-glomerular basement membrane disease after alemtuzumab.New England Journal of Medicine. 2008; 359: 768-769
Coles A. Alemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 years. Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Dusseldorf, Germany; 2009.
- Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.New England Journal of Medicine. 2008; 359: 1786-1801
- The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.Journal of Neurology. 2006; 253: 98-108
- The occurrence of autoimmune diseases in patients with multiple sclerosis and their families.Journal of Clinical Neuroscience. 2000; 7: 434-437
- Goodpasture's syndrome associated with multiple sclerosis.Acta Neurologica Scandinavica. 1998; 98: 134-135
- IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).Journal of Clinical Investigation. 2009; 119: 2052-2061
- Anti-GBM antibody mediated disease.in: Wilkinson R J.R. Nephrology. Chapman and Hall, London1997: 599-615
- Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.Annals of Internal Medicine. 2001; 134: 1033-1042
- Anti-glomerular basement membrane disease: role of enzyme-linked immunosorbent assays in diagnosis.Biochemical and Molecular Medicine. 1996; 59: 52-56
Meyer D, Coles A, on behalf of the CAMMS223 Study Group. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment. Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Gothenburg, Sweden; 2010.
- Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells.Journal of Autoimmunity. 2008; 31: 295-300
- Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis.New England Journal of Medicine. 2010; 363: 343-354
- Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays.Nephrology Dialysis Transplantation. 2006; 21: 397-401
Article info
Publication history
Accepted:
July 19,
2012
Received:
June 15,
2012
Identification
Copyright
© 2012 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
